{"component": "definition", "props": {"groups": [{"samples": [{"hash": "2hQpDZGFmFG", "uri": "/contracts/2hQpDZGFmFG#delivery-technology", "label": "Joint Venture Agreement", "score": 36.5126635258, "published": true}, {"hash": "6cpG9OzxjWM", "uri": "/contracts/6cpG9OzxjWM#delivery-technology", "label": "Crispr Ip Contribution Agreement", "score": 31.3408622742, "published": true}, {"hash": "gsHTLCOvxrw", "uri": "/contracts/gsHTLCOvxrw#delivery-technology", "label": "Joint Venture Termination Agreement (CRISPR Therapeutics AG)", "score": 31.1136207581, "published": true}], "size": 9, "snippet_links": [{"key": "licensed-agent", "type": "definition", "offset": [93, 107]}, {"key": "the-human", "type": "clause", "offset": [134, 143]}], "snippet": "means methods, formulations, technologies and systems, including vectors, for transporting a Licensed Agent or Product into or within the human body or into human cells outside of the body.", "hash": "ccdb3000e402a6309826769554101a4c", "id": 1}, {"samples": [{"hash": "8n1hqPgGdOs", "uri": "/contracts/8n1hqPgGdOs#delivery-technology", "label": "Collaboration Agreement", "score": 32.0863380432, "published": true}, {"hash": "8iL1py4wbnz", "uri": "/contracts/8iL1py4wbnz#delivery-technology", "label": "Collaboration Agreement (BioNTech SE)", "score": 31.5516777039, "published": true}], "size": 5, "snippet_links": [{"key": "applicable-to", "type": "clause", "offset": [28, 41]}, {"key": "delivery-of", "type": "clause", "offset": [82, 93]}, {"key": "in-vivo", "type": "definition", "offset": [129, 136]}, {"key": "for-clarity", "type": "clause", "offset": [138, 149]}], "snippet": "means the BioNTech Know-How applicable to formulating nucleic acids to enable the delivery of such nucleic acids to target cells in vivo. For clarity, Delivery Technology does not include [***].", "hash": "5f725b9d883cdbd42d85bc9792c4b42c", "id": 2}, {"samples": [{"hash": "73Xp2uQFMkw", "uri": "/contracts/73Xp2uQFMkw#delivery-technology", "label": "Statement of Work and License Agreement (Enochian Biosciences Inc)", "score": 32.3045845032, "published": true}, {"hash": "2xJ2psp6QgU", "uri": "http://pdf.secdatabase.com/2411/0001731122-21-000640.pdf", "label": "pdf.secdatabase.com", "score": 10.8699522018, "published": false}, {"hash": "lEAK4Ul9cr9", "uri": "https://qm.kscope.io/downloadDoc?docid=115805451&CK=1527728&format=pdf", "label": "qm.kscope.io", "score": 10.6522932053, "published": false}], "size": 3, "snippet_links": [{"key": "by-licensor", "type": "clause", "offset": [37, 48]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [49, 73]}, {"key": "to-the-extent", "type": "clause", "offset": [111, 124]}, {"key": "delivery-of", "type": "clause", "offset": [210, 221]}, {"key": "each-case", "type": "definition", "offset": [362, 371]}, {"key": "in-vivo", "type": "definition", "offset": [388, 395]}, {"key": "for-the-purposes-of", "type": "clause", "offset": [406, 425]}, {"key": "the-foregoing", "type": "clause", "offset": [573, 586]}], "snippet": "means all Know-How Rights Controlled by Licensor as of the Effective Date or during the term of this Agreement to the extent Covering (a) formulating nucleic acids into applicable gene constructs to enable the delivery of such nucleic acids specifically by utilizing (i) AAV-mediated gene transduction technology or (ii) nanoparticle DNA delivery technology, in each case to target cells in vivo in humans for the purposes of one or more Indications; or (b) techniques, methodologies, procedures or processes for such delivery for such purposes; or (c) any Improvements to the foregoing.", "hash": "f76c08243d9db273d7cb3b47a7642a9d", "id": 3}, {"samples": [{"hash": "fSDlRsaQplS", "uri": "/contracts/fSDlRsaQplS#delivery-technology", "label": "Collaboration and License Agreement (Verve Therapeutics, Inc.)", "score": 32.4031486511, "published": true}, {"hash": "eqMgVzwNYhN", "uri": "/contracts/eqMgVzwNYhN#delivery-technology", "label": "Collaboration and License Agreement (Verve Therapeutics, Inc.)", "score": 32.2881584167, "published": true}], "size": 2, "snippet_links": [{"key": "with-respect-to", "type": "clause", "offset": [11, 26]}], "snippet": "means, (a) with respect to Beam, the Beam Delivery Technology and (b) with respect to Verve, the Verve Delivery Technology.", "hash": "dabccd879f0168ba63885c21cc508f23", "id": 4}, {"samples": [{"hash": "eCKenATOPpz", "uri": "/contracts/eCKenATOPpz#delivery-technology", "label": "Research and License Agreement (Megabios Corp)", "score": 18.0, "published": true}, {"hash": "cN4AYL7XFjY", "uri": "/contracts/cN4AYL7XFjY#delivery-technology", "label": "Research and License Agreement (Megabios Corp)", "score": 18.0, "published": true}], "size": 2, "snippet_links": [{"key": "technical-information", "type": "definition", "offset": [6, 27]}, {"key": "relate-to", "type": "definition", "offset": [88, 97]}, {"key": "delivery-systems", "type": "definition", "offset": [115, 131]}], "snippet": "means technical information, ------------ inventions, materials, data and know-how that relate to Lipid-based gene delivery systems.", "hash": "9e1032c1eb6a7ee321f1abead20d43c5", "id": 5}, {"samples": [{"hash": "1Pd6D2Qm14j", "uri": "/contracts/1Pd6D2Qm14j#delivery-technology", "label": "License and Joint Development Agreement (Spectrx Inc)", "score": 18.0, "published": true}], "size": 2, "snippet_links": [{"key": "delivery-of", "type": "clause", "offset": [59, 70]}, {"key": "living-organism", "type": "definition", "offset": [89, 104]}, {"key": "not-limited", "type": "clause", "offset": [120, 131]}, {"key": "drug-substances", "type": "definition", "offset": [153, 168]}, {"key": "right-to-license", "type": "clause", "offset": [214, 230]}, {"key": "pursuant-to-this-agreement", "type": "clause", "offset": [231, 257]}], "snippet": "means TECHNOLOGY that is useful in transdermal/intradermal delivery of substances into a living organism including, but not limited to, human beings for drug substances (but not tattoos), which ALTEA owns with the right to license pursuant to this Agreement.", "hash": "151fa5aeaa8c012b83f8b3855065ecf1", "id": 6}, {"samples": [{"hash": "la3djpAZR9V", "uri": "/contracts/la3djpAZR9V#delivery-technology", "label": "License and Collaboration Agreement (I-Mab)", "score": 31.9158115387, "published": true}], "size": 1, "snippet_links": [{"key": "delivery-system", "type": "definition", "offset": [10, 25]}, {"key": "mechanical-components", "type": "clause", "offset": [96, 117]}, {"key": "time-release", "type": "definition", "offset": [252, 264]}, {"key": "each-case", "type": "definition", "offset": [281, 290]}, {"key": "to-assist", "type": "clause", "offset": [297, 306]}, {"key": "administration-of", "type": "clause", "offset": [314, 331]}, {"key": "licensed-compound", "type": "definition", "offset": [334, 351]}, {"key": "licensed-product", "type": "definition", "offset": [355, 371]}], "snippet": "means any delivery system comprising equipment, instrumentation, one (1) or more devices, other mechanical components (such as a syringe or infusion bag) or delivery technology comprising a mode, method or material for administration (such as depot or time release technology), in each case, used to assist in the administration of a Licensed Compound or Licensed Product.", "hash": "bbbeb79372a74f67375b0e81978fa9d6", "id": 7}, {"samples": [{"hash": "absHN1ffB62", "uri": "/contracts/absHN1ffB62#delivery-technology", "label": "License and Collaboration Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 21.0, "published": true}], "size": 1, "snippet_links": [{"key": "patent-rights", "type": "clause", "offset": [10, 23]}, {"key": "rnai-compound", "type": "definition", "offset": [143, 156]}, {"key": "for-treatment", "type": "clause", "offset": [157, 170]}], "snippet": "means the Patent Rights and Know-How that are necessary or useful for delivering or administering any pharmaceutical formulation containing an RNAi Compound for treatment, palliation or prophylaxis of an Indication.", "hash": "63cd9a5c8f11392bed2c6ff2c16a76bd", "id": 8}, {"samples": [{"hash": "daLqhLoXyhZ", "uri": "/contracts/daLqhLoXyhZ#delivery-technology", "label": "Strategic Advisor & Transition Agreement (Moderna, Inc.)", "score": 28.1937026978, "published": true}], "size": 1, "snippet_links": [{"key": "the-research", "type": "clause", "offset": [27, 39]}, {"key": "delivery-vehicles", "type": "clause", "offset": [95, 112]}, {"key": "nucleic-acid", "type": "definition", "offset": [117, 129]}, {"key": "prior-inventions", "type": "clause", "offset": [221, 237]}, {"key": "complete-list", "type": "clause", "offset": [257, 270]}, {"key": "inventions-or-improvements", "type": "definition", "offset": [278, 304]}, {"key": "subject-matter", "type": "clause", "offset": [321, 335]}, {"key": "employment-by-the-company", "type": "clause", "offset": [342, 367]}, {"key": "to-practice", "type": "clause", "offset": [418, 429]}, {"key": "prior-to", "type": "definition", "offset": [465, 473]}, {"key": "engagement-by-the-company", "type": "clause", "offset": [477, 502]}, {"key": "no-inventions", "type": "clause", "offset": [506, 519]}, {"key": "patent-filings", "type": "clause", "offset": [563, 577]}, {"key": "with-respect-to", "type": "clause", "offset": [670, 685]}, {"key": "relationship-with-the-company", "type": "clause", "offset": [772, 801]}, {"key": "a-list", "type": "definition", "offset": [848, 854]}, {"key": "patents-and-patent-applications", "type": "definition", "offset": [862, 893]}], "snippet": "means technology regarding the research, development, manufacture, use or commercialization of delivery vehicles for nucleic acid--based cargo. To: ModernaTX, Inc. From: \u2587\u2587\u2587\u2587 \u2587\u2587\u2587\u2587\u2587\u2587\u2587\u2587 Date: _____________________ SUBJECT: Prior Inventions The following is a complete list of all inventions or improvements relevant to the subject matter of my employment by the Company that have been made or conceived or first reduced to practice by me alone or jointly with others prior to my engagement by the Company: \u008f No inventions or improvements \u008f See below: PCT and other patent filings for Fate Therapeutics (cell based therapies), and aTyr (new biologics and pathways) My work with respect to use of transporters, ion channels and carriers to treat diseases prior to my services relationship with the Company \u008f Additional sheets attached The following is a list of all patents and patent applications in which I have been named as an inventor: \u008f None \u008f See below: see above______________________________________________ _______________________________________________________________ _______________________________________________________________", "hash": "95b82008cc958a94ae1c7f1aa0a889bb", "id": 9}, {"samples": [{"hash": "cejWDvdh5CR", "uri": "/contracts/cejWDvdh5CR#delivery-technology", "label": "Joint Venture Agreement (CRISPR Therapeutics AG)", "score": 27.7652301788, "published": true}], "size": 1, "snippet_links": [{"key": "licensed-agent", "type": "definition", "offset": [93, 107]}, {"key": "the-human", "type": "clause", "offset": [134, 143]}, {"key": "certain-confidential-information", "type": "clause", "offset": [198, 230]}, {"key": "contained-in", "type": "definition", "offset": [231, 243]}, {"key": "omitted-and-filed-separately-with-the-securities-and-exchange-commission", "type": "clause", "offset": [288, 360]}, {"key": "pursuant-to-rule", "type": "clause", "offset": [361, 377]}, {"key": "securities-act-of-1933", "type": "definition", "offset": [389, 411]}, {"key": "as-amended", "type": "definition", "offset": [413, 423]}], "snippet": "means methods, formulations, technologies and systems, including vectors, for transporting a Licensed Agent or Product into or within the human body or into human cells outside of the body. [***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.", "hash": "085ffc2a0a8a6e0ee7090534e58f8669", "id": 10}], "next_curs": "CmASWmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjwLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIcZGVsaXZlcnktdGVjaG5vbG9neSMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"size": 26, "title": "Delivery Technology", "snippet": "means methods, formulations, technologies and systems, including vectors, for transporting a Licensed Agent or Product into or within the human body or into human cells outside of the body.", "id": "delivery-technology", "examples": ["Confidentiality of information disclosed between Introgen and Gendux shall be governed by Section 11 of the <strong>Delivery Technology</strong> License Agreement.", "Beam shall have the sole right to initiate and prosecute such legal action at its own expense and in the name of Beam and, if requested by Beam in the name of Verve, or to control the defense of any declaratory judgment action relating to Beam Base Editor Technology, Beam Collaboration Technology and Beam <strong>Delivery Technology</strong>.", "All milestone payments are payable only once under this Agreement for each <strong>Delivery Technology</strong> Product to achieve such milestone.", "Beam acknowledges and agrees that, if any of the licenses granted to Verve under the Verve Third Party Agreements are terminated, in whole or in part, then, to the extent that any Patent Rights or Know-How licensed under such terminated license is part of Verve <strong>Delivery Technology</strong> hereunder, then Beam\u2019s license under such terminated licenses(s) shall automatically terminate, subject to any right of Beam to receive a direct license from the relevant Third Party.", "The term of this Agreement (the \u201cTerm\u201d) will commence on the Effective Date and extend, unless this Agreement is terminated earlier in accordance with this Article 15, until the last to expire of any Royalty Term for any Product or <strong>Delivery Technology</strong> Product in the Territory.", "The grantee Party shall be required to provide the notice described in clause (a) of this Section 9.2 within [**] of the effective date of an agreement or arrangement under which the grantee Party or its Affiliate is granted rights to any Patent Right or Know-How that would be <strong>Delivery Technology</strong> hereunder if accepted by the other Party.", "Ownership of all Product <strong>Delivery Technology</strong> and any other Program Technology and Patent Rights with respect thereto shall be determined in accordance with Section 7.6 it being understood that the owner thereof shall have the exclusive right to use such Program Technology and Patent Rights outside the Collaboration.", "All matters relating to patent applications with respect to Inventions shall be governed by Section 7.4 of the <strong>Delivery Technology</strong> License Agreement.", "For such purposes, a breach of the Target Gene License Agreement, the <strong>Delivery Technology</strong> License Agreement or the Services Agreement shall be deemed a breach of this Agreement.", "Subject to the license granted to Beam under Sections 2.1.2, 2.1.3 and 6.3, the entire right, title and interest in and to the Verve Collaboration Technology, Verve <strong>Delivery Technology</strong> and the Clinical Trial Data shall be owned solely by Verve."], "related": [["manufacturing-technology", "Manufacturing Technology", "Manufacturing Technology"], ["licensed-technology", "Licensed Technology", "Licensed Technology"], ["background-technology", "Background Technology", "Background Technology"], ["licensor-technology", "Licensor Technology", "Licensor Technology"], ["licensee-technology", "Licensee Technology", "Licensee Technology"]], "related_snippets": [], "updated": "2025-07-10T05:58:13+00:00"}, "json": true, "cursor": ""}}